Clinical Proteomics From Diagnosis to Therapy

"... an essential multi-authored book (136 authors), edited by two individuals with a large and particularly well-recognized expertise in all 'proteomic fields'... Such an impressive overview of most of the relevant characteristics of clinical proteomics, the quality (as well as the homogeneity) of the texts, the generally beautiful pictures illustrating the different chapters make the book an important source of information for everybody interested in clinical proteomics as well as in translational medicine." BIOTECHNOLOGYUnparalleled in its scope and depth, this book brings together proteomic approaches use in the discovery and development of diagnostic and prognostic biomarkers that are applicable to all clinical fields.Following an overview of state-of-the-art technologies and strategies currently being applied to clinical proteomics, the book focuses on individual diseases including cancer, diabetes, stroke and cardiopulmonary, renal and autoimmune diseases as well as clinical toxicology finishing with a discussion of the future of clinical proteomics. This new discipline in molecular medicine holds promise to revolutionize the practice of medicine and this book is a first.

Jennifer Van Eyk is the Director of the Johns Hopkins Bayview Proteomics Center and Professor of Medicine, Biological Chemistry and Biomedical Engineering at Johns Hopkins University in Baltimore, Maryland. She has developed novel methods to investigate heart disease including preconditioning, ischemic injury and heart failure with emphasis on both understanding the underlying pathological mechanism and for the development of diagnostic biomarkers. Dr. Van Eyk sits on numerous editorial boards including Proteomics, Proteomics: clinical application, Journal of Physiology and Circulation Research.



Michael J. Dunn was recently appointed as Professor of Biomedical Proteomics at University College, Dublin (Ireland), where he is doing proteomics research in the areas of cardiovascular disease, transplantation and neurological disease. Prior to his move to Dublin, he was Professor of Proteomics at the Institute of Psychiatry, King's College London.
Dr. Dunn is the current President of the British Society for Proteome Research and the Editor-in-Chief of the journal Proteomics. He is also a founder Council Member of the Human Proteome Organisation (HUPO) and a member of the Executive Committee of the HUPO Brain Proteome Project (BPP).